ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.033,28
0,07%
S&P 500
5.431,60
-0,04%
Dow Jones
38.589,16
-0,15%
Euro vs US Dollar
1,07104
0,08%
Bitcoin
65.670,11
-1,45%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. KalVista Pharmaceuticals Inc (KALV)

  7. KalVista Pharmaceuticals Inc (KALV) News

KALV

KalVista Pharmaceuticals (KALV)

KalVista Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:KALV
DatumZeitQuelleÜberschriftSymbolFirma
11/06/202400h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
06/06/202412h30Business WireKalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024NASDAQ:KALVKalVista Pharmaceuticals Inc
04/06/202412h30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
03/06/202412h30Business WireKalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024NASDAQ:KALVKalVista Pharmaceuticals Inc
31/05/202422h09Business WireKalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary AngioedemaNASDAQ:KALVKalVista Pharmaceuticals Inc
31/05/202418h15Business WireKalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary AngioedemaNASDAQ:KALVKalVista Pharmaceuticals Inc
24/05/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
24/05/202422h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
24/05/202412h30Business WireKalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024NASDAQ:KALVKalVista Pharmaceuticals Inc
21/05/202423h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
21/05/202423h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
21/05/202423h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
21/05/202423h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
21/05/202412h30Business WireKalVista Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:KALVKalVista Pharmaceuticals Inc
02/05/202412h30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
01/05/202412h30Business WireKalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal YearNASDAQ:KALVKalVista Pharmaceuticals Inc
22/04/202412h30Business WireKalVista Pharmaceuticals Appoints William C. Fairey to Board of DirectorsNASDAQ:KALVKalVista Pharmaceuticals Inc
03/04/202412h30Business WireKalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:KALVKalVista Pharmaceuticals Inc
02/04/202412h30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
18/03/202411h30Business WireKalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference AmericasNASDAQ:KALVKalVista Pharmaceuticals Inc
12/03/202411h30Business WireKalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for SebetralstatNASDAQ:KALVKalVista Pharmaceuticals Inc
11/03/202421h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
11/03/202421h26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KALVKalVista Pharmaceuticals Inc
11/03/202411h30Business WireKalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational UpdateNASDAQ:KALVKalVista Pharmaceuticals Inc
08/03/202422h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
08/03/202412h30Business WireKalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference AmericasNASDAQ:KALVKalVista Pharmaceuticals Inc
07/03/202412h38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
07/03/202412h30Business WireKalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive OfficerNASDAQ:KALVKalVista Pharmaceuticals Inc
06/03/202412h30Business WireKalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:KALVKalVista Pharmaceuticals Inc
04/03/202412h30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:KALV

Kürzlich von Ihnen besucht

BIT
C00122
Commerzbank
BIT
P1DDD3
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten